These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1016 related items for PubMed ID: 21895543

  • 21. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
    Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F, LYM-3002 investigators.
    Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M, Chen Y, Huang H, Zhou X, Liu J, Huang G.
    Oncotarget; 2016 Dec 13; 7(50):83544-83553. PubMed ID: 27835875
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.
    Aoki K, Takahashi T, Tabata S, Kurata M, Matsushita A, Nagai K, Ishikawa T.
    Leuk Lymphoma; 2013 Nov 13; 54(11):2441-7. PubMed ID: 23452117
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone.
    Chae YS, Shin H, Sohn SK, Lee SJ, Moon JH, Kang BW, Kim JG, Yang DH, Lee JJ, Park TI.
    Leuk Lymphoma; 2012 Sep 13; 53(9):1757-63. PubMed ID: 22372848
    [Abstract] [Full Text] [Related]

  • 27. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli A, Martelli M.
    Clin Lymphoma Myeloma; 2009 Oct 13; 9(5):381-5. PubMed ID: 19858058
    [Abstract] [Full Text] [Related]

  • 28. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.
    Derenzini E, Stefoni V, Pellegrini C, Fina MP, Broccoli A, Venturini F, Gandolfi L, Pileri SA, Martelli M, Petti MC, Perrotti A, De Renzo A, Zaja F, Baccarani M, Zinzani PL.
    Leuk Lymphoma; 2009 Nov 13; 50(11):1824-9. PubMed ID: 19814687
    [Abstract] [Full Text] [Related]

  • 29. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM, Bar-Shalom R.
    Am J Hematol; 2013 May 13; 88(5):400-5. PubMed ID: 23423884
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study.
    Chang JE, Seo S, Kim KM, Werndli JE, Bottner WA, Rodrigues GA, Sanchez FA, Saphner TJ, Longo WL, Kahl BS.
    Clin Lymphoma Myeloma Leuk; 2010 Oct 13; 10(5):379-84. PubMed ID: 21030351
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
    Sehn LH, Martelli M, Trněný M, Liu W, Bolen CR, Knapp A, Sahin D, Sellam G, Vitolo U.
    J Hematol Oncol; 2020 Jun 06; 13(1):71. PubMed ID: 32505213
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
    Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, MabThera International Trial (MInT) Group.
    Lancet Oncol; 2011 Oct 06; 12(11):1013-22. PubMed ID: 21940214
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 51.